The Case of Katherine

View more case examples here

Download our brochures here (PDF)

Patient Presentation
Katherine had been diagnosed with non-small cell lung cancer (NSCLC) and was offered standard chemotherapy. We suggested that she get tested for EGFR mutations. Katherine was then found to have EGFR positive NSCLC via a biopsy test provided to her by her public medical system oncologist.

Based on this data, her public medical system Oncologist had tried her on the 1st generation EGFR inhibitor Tarceva, which Katherine stopped responding to after 8 months.

Her Oncologist told her that the standard chemotherapeutic drugs would provide her with temporary relief, but would not stop the progression of her disease. She started out on a platinum based regime, but the side effects were too strong, and a CT scan showed disease progression.

Katherine wasn’t ready to just accept this and so she reached out to us again.

How we helped Katherine using our 6 step system

1. Introduced advanced diagnostics
First, we arranged for a detailed genetic test, and identified that Katherine’s cancer had the EGFR T790M gatekeeper mutation, which confers resistance to first generation EGFR TKIs.

2. Clinical Trial Research
We then researched and identified a third generation EGFR TKI that was achieving significant results in patients with T790M mutations and was designed for this EGFR mutation.

3. Clinical Trial support
Unfortunately, a test biopsy performed by the trial coordinators (in which they did not use PET/CT data to ensure they had accessed tumour tissue) did not identify the required T790M mutation, and Katherine was excluded from the trial due to this error.

4. Interim Treatment Support
Based on our research we did on Katherine’s behalf, we immediately directed her oncologist to use a targeted drug combination (in this case, Tarceva and Avastin) which had been reported to delay progression in patients with T790M mutations, and as such Katherine was given this drug combination until a suitable trial was found.

5. Genetic Testing During Treatment
We provided a liquid biopsy to identify her current EGFR mutational status.

6. Clinical Trial Support and Advocacy
Meanwhile, we contacted the makers of a 3rd generation EGFR T790M inhibitor, and another competing drug company. After presenting our case, including the genetic data we had collected and the personalized research we had conducted on Katherine’s behalf, she was contacted and offered clinical trial positions from both companies, as well as the potential for compassionate access.

Katherine is currently taking one of the trial drugs. Since the drug is an oral pill, she is able to do the trial from a distance, and stay at her home in Canada. The drug is working very well for Katherine and is known to delay disease progression significantly, reduce hospital visits, and increase comfort as it is a non-chemotherapy targeted drug.

The compassionate access we have arranged will also mean reduced cost to Katherine and her family, and she can get the treatment she needs with much less stress and financial strain.

Our research has just has identified another 3rd generation EGFR drug which, when taken after failure of her current drug, has been shown to significantly increase survival rates.


As you can see, a CTOAM records review and consultation can result in significant benefits to a patient’s outcome. Having access to a team of knowledgeable scientists, doctors, and patient advocates that WORK FOR YOU and NOT THE MEDICAL SYSTEM can make all the difference in the outcome of your disease!

If you or a loved one is fighting cancer, give us a call so we can do a brief review of your medical records. It is important to be sure that you KNOW that you are doing all you can, and that you have access to the best treatments for your own unique case. (778) 999-5463